Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 21,412 matching trials from the live ClinicalTrials.gov search.
Conditions
Type 2 Diabetes Mellitus
Interventions
placebo, Exenatide LAR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
7
States / cities
Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more
Conditions
Cystic Fibrosis
Interventions
JBT-101 (lenabasum), Placebo
Drug · Other
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 8 more
Active, not recruiting Phase 1Phase 2 Interventional Results available

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

NCT05192889
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Dasatinib, Cytarabine, Blinatumomab, Methotrexate, Mercaptopurine, Cyclophosphamide, Etoposide, Leucovorin, Intrathecal Triples, Pegaspargase, Erwinia asparaginase, Radiation
Drug · Biological · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
4 Years to 30 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Memphis, Tennessee
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Advanced Endometrial Adenocarcinoma, Stage III A, B, C
Interventions
Docetaxel and Carboplatin
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Greenville, South Carolina • Roanoke, Virginia
Conditions
Breast Cancer
Interventions
conventional surgery, neoadjuvant therapy, radiofrequency ablation
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Sacramento, California
Conditions
Cutaneous T-cell Lymphoma (CTCL),
Interventions
Forodesine 200 mg
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
19
States / cities
Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 16 more
Conditions
Acute Myeloid Leukemia
Interventions
Alisertib, Cytarabine, Idarubicin, Daunorubicin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Leukemia, Lymphoma
Interventions
rituximab, bryostatin 1
Biological · Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Phase II Trial of Pentostatin and Targeted Busulfan

NCT00496340
Conditions
Hematologic Malignancies
Interventions
Pentostatin, Busulfan, Rituximab, Allogeneic Hematopoietic Cell Transplant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Head and Neck
Interventions
Hydroxyurea, 5- Fluorouracil, Cisplatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
59 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Vinorelbine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Conditions
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine
Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more
Conditions
Acute Stroke, Ischemic Stroke, Stroke
Interventions
Recombinant human tissue kallikrein, Placebo for DM199 Solution for Injection
Drug · Other
Lead sponsor
DiaMedica Therapeutics Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
36
States / cities
Fairhope, Alabama • Arcadia, California • Glendale, California + 29 more
Conditions
Alzheimer's Disease
Interventions
PRX-03140, Donepezil, Placebo
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • National City, California + 28 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Conditions
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Interventions
Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Squamous Cell of the Head and Neck
Interventions
REOLYSIN®, Carboplatin, Paclitaxel
Biological · Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Conditions
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Lenvatinib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
Interventions
NGM120 Q4W, NGM120 Q8W, Placebo given
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Santa Rosa, California • Margate, Florida + 9 more
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Prednisone or methylprednisolone
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 29 more
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions
Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Temsirolimus, Vinorelbine Tartrate
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 29 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
163
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Comprehensive Geriatric Assessment, Health Education, Medical Device Usage and Evaluation, Supportive Care
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Systemic Sclerosis-Associated PAH
Interventions
Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
Biological · Other · Diagnostic Test + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more